Ginsenoside Rf Promotes Testosterone Synthesis Through the cAMP/PKA/CREB Signaling Pathway to Improve Obesity-Related Male Hypogonadism

A ginseng-derived compound raised testicular testosterone in high-fat-diet mice by activating the cAMP/PKA/CREB pathway — no human data yet

Journal: Biochemical Pharmacology | Published: 2026-01-28 | Type: Animal study | PMID: 41617094 Authors: Runqi Zhang, Xiaoxing Zheng, Yuqing Chen, Xiangyu Qi, Chenglin Lu, Qingbo Guan, Chunxiao Yu (Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Shandong Provincial Hospital, Shandong University of Traditional Chinese Medicine) Funding/COI: Funding not disclosed. Authors declare no competing financial interests.

Summary

This study tested Ginsenoside Rf — a compound extracted from ginseng — in male mice made obese via high-fat diet, and found it reduced testicular lipid deposition and raised testosterone by activating the cAMP/PKA/CREB signaling cascade. The mechanism was partially validated in cultured Leydig cells using a PKA inhibitor to confirm pathway specificity. This is entirely preclinical: there are no human subjects, no pharmacokinetic data, and no dose-response curve translatable to a clinical setting.

Claims

• Mice fed a high-fat diet for 12 weeks and then treated with Ginsenoside Rf for 5 weeks showed reduced body weight and less testicular stromal lipid deposition compared to untreated HFD controls
• Rf-treated mice had increased intratesticular testosterone and upregulated expression of steroidogenic proteins: Star, Srb1, Cyp11a1, and Cyp17a1
• In palmitic acid (PA)-stressed Leydig cells in vitro, Rf elevated phosphorylated PKA (p-PKA) and the p-CREB/CREB ratio alongside Star and Cyp11a1
• These in vitro effects were reversed by H89, a PKA inhibitor, supporting pathway specificity
• Network pharmacology (computational analysis) independently flagged Star, Cyp11a1, and cAMP signaling as probable targets

Study Quality

This is a mechanistic mouse study with a clean three-arm design (normal diet, HFD, HFD + Rf) and a plausible pathway-level explanation supported by both in vivo and in vitro experiments. Using H89 to block PKA and observing reversal of Rf's effects is a reasonable method for establishing pathway dependence, not just correlation. The network pharmacology component is hypothesis-generating at best — it identified the same targets the wet-lab experiments tested, which means it added limited independent validation.

The study does not report the dose of Ginsenoside Rf administered, bioavailability data, or how testicular testosterone was measured (immunoassay, LC-MS, or otherwise). No sample sizes for the mouse groups are stated in the abstract. There is no sham or vehicle control for the Rf arm to distinguish drug effect from gavage stress. The 5-week intervention window is short and follows 12 weeks of HFD, leaving open whether the testosterone improvement reflects direct steroidogenic stimulation or a secondary consequence of weight reduction.

Red Flags

• No human data. Findings in HFD mice do not predict clinical efficacy in men with obesity-related hypogonadism
• Funding not disclosed. Unusual omission for a pharmacology paper; potential for undisclosed industry interest in a ginseng-derived compound
• Network pharmacology laundering. Computational target prediction is dressed up as mechanistic support, but it confirmed what the bench work already tested — it adds no independent evidence
• Weight loss confound. Rf reduced body weight; lower adiposity alone can raise testosterone in obese men. The paper does not isolate the steroidogenic effect from the metabolic effect
• Dose not reported in abstract. Cannot assess whether the administered dose is pharmacologically plausible in humans
• Single-compound, single-pathway framing. Ginseng contains dozens of ginsenosides with overlapping bioactivity; attributing effects cleanly to Rf requires more rigorous controls than presented

Strengths

• In vitro PKA inhibition experiment provides mechanistic grounding beyond pure association
• Measured multiple steroidogenic enzymes (Star, Srb1, Cyp11a1, Cyp17a1), not just testosterone as an endpoint
• Addresses a real and understudied problem: obesity-related secondary hypogonadism has few targeted pharmacologic options
• Uses an established obesity model (HFD-induced) with a reasonable intervention timeline

Verdict

This is early-stage mechanistic work in mice that proposes a plausible pathway for how Ginsenoside Rf might support testosterone synthesis in the context of metabolic obesity. The PKA inhibitor experiment is the most credible element. Everything else — the network pharmacology, the weight-loss confound, the missing dose information, the undisclosed funding — makes this a hypothesis paper, not evidence of efficacy. File it under "interesting enough to watch if a proper pharmacokinetic and dose-finding study follows." Do not confuse a mouse gaining testosterone with a man doing the same.